Sartorius Stedim Biotech : Weak finish as expected, stabilisation of order book, outlook good
>Q4 sales weak as expected, order intake to stabilise - Q4 revenues of € 706m (-20.7% y-o-y, 0%/2% vs ODDO BHF/consensus) were impacted by a constant currency decline of 17.8%. Excluding Covid-headwind, the decline in revenue would have been at around 14% in the first half. Sartorius Stedim Biotech was significantly impacted by the expected inventory reductions and a general reluctance to invest on the part of customers. Order intake of € 716m (flat y-o-y) was in lin...Sartorius Stedim Biotech is a provider of equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Co.'s solutions cover fermentation, filtration, purification, fluid management and lab technologies and membrane chromatography, including various conventional lab products to biopharmaceutical laboratories. Co.'s technologies, products and services are used to develop and manufacture medications and vaccines using biological methods. Co.'s products covers all upstream and downstream steps in the production of active pharmaceutical ingredients. It specializes in single-use products and offers technical consulting and services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.